HEBIAS targets the highest possible societal health gain related to innovative drugs, medical devices and diagnostic tests …
… by providing guidance from the set-up of clinical studies through post-launch as well as classic market access consultancy.
The world of medicinal products is becoming increasingly complex due to fixed/predetermined government budgets and strained social security systems.
This evolution is accompanied by stricter regulations and more stringent controls of the actual efficacy of medication. Pharmaceutical companies have a vested interest in positioning their new medicinal products, medical devices and diagnostic tests based on the greatest possible societal gains.
HEBIAS is a strategic partner for pharmaceutical companies, and can advise at an early stage on how data collection and target group segmentation may result in more optimal market access for medicinal products and medical devices in Belgium and Luxembourg.
In order to enable pharmaceutical companies to penetrate the market more efficiently following marketing authorisation, HEBIAS makes its research results available via dynamic, tailored models that chart potential cost-effectiveness scenarios.
For pharmaceutical companies who desire it, HEBIAS also offers classic consultancy services for market access that begins only after clinical data has been collected.